MOSCOW (MRC) -- Essen-based Evonik Industries, a leading specialty chemicals manufacturer, invested over EUR400 mln in its plants in Germany in 2015, said the producer in its press release.
Last year, Evonik once again demonstrated its considerable power to create at its German sites. Thus, according to a recent projection, the company invested more than EUR 400 million in its domestic production plants. The lion’s share of the funds (around two-thirds) was divided among Evonik’s five-largest sites in Germany: Marl (hundreds of millions of euros), Hanau, Essen, Darmstadt, and Wesseling (tens of millions of euros at each site).
"By investing in growth and modernization in Germany, we are strengthening our foothold in important markets of the future," stressed Klaus Engel, Chairman of Evonik’s Executive Board. "Favorable conditions for investment are by no means a given. I would like to see greater understanding among policy-makers for the necessary competitiveness of our industry, entailing, for example, improvements in the transportation infrastructure, the transition to renewable energy sources, and the expansion of digital networks."
Evonik is planning further large-scale projects in Germany. One of these is the construction of a new plant for production of specialty copolyesters in Witten by 2018 with an investment in the double-digit million euro range. As part of the global production initiative for specialty silicones, Evonik intends to invest in production for these products in Essen once again. A new silane research center is currently being built in Rheinfelden that is slated to be completed in 2016.
As MRC wrote previously, in Marl, Evonik’s largest site worldwide with a workforce of close to 7,000, a production facility for C4-based raw materials was completed in 2015. In Essen, the company put a new manufacturing plant for polymeric dispersants into operation and expanded a plant in which specialty silicones are produced.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around EUR12.9 billion and an operating profit (adjusted EBITDA) of about EUR2.0 billion.
MRC